MENY
Administratör Logga ut

PAVO-MMY1004

Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.

PAVO-MMY1004
An Open-label, Multicenter, Dose Escalation Phase 1b study to Access the Safety and Pharmacokinetics of Subcutaneous Delivery of Daratumumab with Addition of Recombinant Human Hyaluronidase(rHuPH20) for the Treatment of Subjects with Relapsed
An Open-label, Multicenter, Dose Escalation Phase 1b study to Access the Safety and Pharmacokinetics of Subcutaneous Delivery of Daratumumab with Addition of Recombinant Human Hyaluronidase(rHuPH20) for the Treatment of Subjects with Relapsed
PLACEHOLDER
Mer information om studien för vårdgivare
Behandling
Fas 1
Ej tillämpbar
Akademisk

Studien ändrades senast av: Birgitta Nässén (2019-05-14)

Tillbaka till listan

Sidan uppdaterad: 14 maj 2019